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In this work, we have used Xenopus oocyte maturation as a read-out for examining the ability of the ncu tyrasine kinase (p185ncu) toparticipate 
with the epidermal growth factor (EGF) receptor in a common signal transduction pdlhay. WC find that unlike the case for the EGF receptor, 
which elicits EGF-depndcnt maturation of these oacytes as reflected by their germinal vesicle breakdown (GVBD). neither the normal neu tyrosine 
kinase (pIBs”lti) nor the oncogenic form ofneu (~185 ulued) are able to effectively trigger this maturation event. However, expression of pl 85ultiM 
causes a specific and significant promotion of the progesterone-induced GVBD. reducing the half-time for this maturation even from -9 h to -S 
h. Stimulation of the progesterone-induced GVBD did not occur following the expression of a kinasc-deficient ~185~” protein (in which a lysine 
residue at position 758 was changed to alanine). Essentially identical results were obtained when the mRN.\s coding for fusion proteins comprised 
of the extracellular domain of the receptor for immunoglobulin E (IgE), and the membrane-spanning and tyrosinc kinase domains of normal or 
oncogenicpl85”‘” (designated IyER/plSS’“‘~ and IyER/p18S~Ub~*. respectively), were injected into oocytcs. Antigen-induced crosslinking of IgER/ 
p185”“(* proteins expressed in oocytes caused a reduction in the half-time for the progesterone-stimulated GVBD from -9 h to -7 h. Thus, the 
aggregation of the membrane-spanning and/or tyrosine kinasc domains of ~185’“‘~“’ partially mimics the effects of the oncogenic forms of p18S”c”. 
Overall, the results of these studies uggest that the activation of the ~185”’ tyrosine kinase by a point mutation within its membrane-spanning 
helix. or an aggregation event, can result in the facilitation ofoocyte maturation events that are elicited by other factors (e.g. progesterone). However, 
the activated p18S”Lu tyrosine kinases are not able to mimic the EGF-stimulated EGF receptor tyrosinc kinase in triggering oocyte maturation, 
which suggests that the EGF receptor and the p185”c” tyrosine kinase do not input into identical signal transduction pathways in these cells. 
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1. INTRODUCTION 
One subclass of the superfamily of growth factor re- 
ceptor/tyrosine kinases (i.e. designated as subclass 1) [ 11, 
which includes the epidermal growth factor (EGF) re- 
ceptor, the pl8P” tyrosine kinase (also referred to as 
erbB-2 or HerZ), and the recently identified erbB-3, has 
received a great deal of attention because of the sus- 
pected involvement of its members in human cancers 
[2,3]. In the case of the neu/erbB-2 and erbB-3 proteins, 
the mechanisms underlying the activation of their tyro- 
sine kinase activities are of interest, particularly because 
specific ligands (growth factors) for these proteins have 
yet to be definitively identified. Interestingly, one spe- 
cific mode of activation of the rat pl85”‘” tyrosine ki- 
nase occurs as an outcome of a single point mutation 
which converts a valine residue at position 664 to a 
glutamic acid. This point mutation is sufficient o elicit 
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oncogenic activity [4], most likely as a result of an in- 
creased tyrosine kinase activity [S-S]. 
A second possible mode of activation of ~185”‘” is 
through a tyrosine kinase cascade. This possibility is 
based on a number of reports which have demonstrated 
that the EGF receptor is able to interact with the ~185”‘~ 
tyrosine kinase [9-131. The existence of such a cascade 
would imply that the EGF receptor and p185”‘” partic- 
ipate in a common signaling pathway. However, studies 
in an interlcukin-3-dependent hematopoietic ell line 
[14] have shown that while the EGF receptor could 
efficiently input into the mitogenic pathways of these 
cells, different forms of neu/erbB-2 could not substitute 
for the EGF-activated EGI; receptor in this system. 
These results then argue t’nat the EGF receptor and 
pl85”‘” in fact participate in distinct signal transduction 
pathways. 
In the present study, we have used the Xenopus oocyte 
system to further address this issue. Opresko and Wiley 
[15] first demonstrated that the expression of the EGF 
receptor tyrosine kinase in oocytes resulted in the re- 
sumption of meiosis as reflected by an EGF-dependent 
stimulation of germinal vesicle breakdown (GVBD). In 
this paper, we have examined whether the translation of 
the mRNA for the normal or the oncogenic p18P 
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tyrosine kinases was able to mimic the EGF receptor 
and elicit a stimulation of GVBD in oocytes. In addi- 
tion, we have examined whether the mRNA coding for 
fusion proteins that contain the extracellular domain of 
the immunoglobulin E (IgE) receptor [16], and the 
membrane-spanning helix and tyrosine kinase domain 
of either the normal or oncogenic forms of pl85”‘“, can 
spontaneously trigger oocyte maturation or modulate 
maturation triggered by other agents (i.e. progesterone). 
2. MATERIALS AND METHODS 
1. I. Oocyrr isohrion and culture 
Xenopus hevis oocytes were dissociated by treatment with collage- 
nase (5 mg/ml, Boehringer-Mannheim) in Barth’s buffer (88 mM 
NaCI, 1 mM KCI, 0.82 mM MgSOJ, 0.33 mM Ca(NO& 0,4l mM 
CaC&, 2.4 mM NaHCO,, 5 mM Tris-HCI, pH 7.4) at 16°C for 5-7 
h. The oocytes were injected with a model NA-1 microinjector (Sutter 
Instrument Co., San Rafael, CA) within 24 h of isolation with 50 nl 
of RNA (per oocyte) or with vehicle (water). 
2.2. Prcpatutiott o/chirtteric DNA constructs 
Constructs containing rat neu DNA (GIu~. Valm, and Valw/ 
Ala75”) in a pSV2-derived vector were generously provided by Dr. 
David Stern (Yale School of Medicine). The vector containing the 
human IgE receptor a-subunit (Fe-GEM) w~is a kind gift from Dr. 
J.-P. Kinct (NIADD. Bethesda, MD), The SPddrivcn EGF receptor 
construct pLOLB, was kindly provided by Dr. H.S. Wiley (Univ. of 
Utah Med. Ctr). Blunt-ended Iv&I-.%/l fragments of the normal and 
oncogenic neu constructs were cloned into a blunted Su/l site in 
pBluescript-, gcncrating pNeuN and pNeuT, respectively. A Seal 
fragment of the pSVNcu (Ala”“) construct was ligated to a fragment 
derived by partial Scat digestion of pNeuN and pNeuT generating 
pN(A758) and pT(A758), respectively. The polymerase chain reaction 
(PCR) was used to synthesize a fragmenr of Fc-GEM. which precisely 
encoded the extracellular domain of the ISE-receptor from the unique 
upstream HindHI site to a novel 3’ linker that replaces regions down- 
stream of the Rrst putative transmembrane r sidue of the IgE receptor 
rr-hubunit with 18 base% encoding the transmembrane s quence of the 
neu gene. Another fragment was synthesized by PCR. upon lhc 
pNeuN and pNeuT construct emplates, to contain as a 5’ boundary 
IS bases of sequence corresponding to the extracellular juxta-mem- 
brane residues of the IgE receptor o-subunit followed by I8 bases of 
sequence corresponding to the transmembrane r gion of the neu gene 
product. The 3’ boundary of these fragments was defined by a linker 
synthesized complementary to a portion of the coding strand of the 
ncu gene including a unique &pEI site. The PCR-derived fragments 
were used in an additional PCR reaction with only the 5’ Fc-GEM 
primer and the 3’ pSVNeu primer to generate a hybrid 650 bp frag- 
ment that encodes the region bearing the entire extracellular domain 
of the IgE receptor o-subunit fused in-frame to the transmembranc 
region 0fpl85~~“. This fragment was digested with Hind111 and BspEI 
and ligated to appropriately digested pNeuN, pNouT, PN(A758), and 
pT(A758) vectors. 
3. RESULTS 
It has been reported that the expression of the human 
EGF receptor in Xenopus oocytes, following the injec- 
tion of the mRNA of the receptor, resulted in the stim- 
uiatioll of mtiotic maturation [IS]. Pig. I shows the 
results from a similar experiment where the mRNA for 
the EGF receptor was generated using the pOBER vec- 






Fig. 1. EGF-stimulated GVBD in oocytes expressing message for 
EGF receptor. 48 h following injection with 50-100 ng of EGF recep- 
tor-encodinp mRNA, oocytcs were exposed to various doses of EGF. 
Times to the onset of GVBD as evidenced by the appearance ofa white 
spot on the animal pole are shown, Control oocytes were exposed to 
5 yg/ml progesterone. Error bars are representative of data from two 
experiments with each data point representing the average of approx- 
imately 20 oocytes. 
cell), as originally described by Opresko and Wiley [l 51. 
While the kinetics of the progesterone-induced GVBD 
differ due to varying culture conditions, the addition of 
nanomolar concentrations of EGF to these oocytes 
caused GVBD about twice as fast as progesterone. Typ- 
ically, we observed an obvious change in the morphol- 
ogy of the oocytes 12-24 h following the addition of 
EGF, ultimately resulting in occyte death. This cyto- 
toxic effect of EGF was eliminated by the nominal rc- 
moval of Ca?+ from the medium, consistent with the 
suggestion of Opresko and Wiley that the EGF-induced 
oocyte degeneration was the outcome of EGF-induced 
changes in the levels of intracellular Ca’+ [15]. 
We have compared the effects of different forms of 
the ~185”‘” tyrosine kinase (Fig. 2) on oocyte matura- 
tion with those elicited by the EGF receptor. Two of 
these forms represented normal ~185”‘” and an onco- 
genie form in which the valine at position 664 was 
changed to a glutamic acid. These arc designated as 
pl 85W1661 and ~185 @6(IJ, respectively. Two other con- 
structs coded for fusion proteins comprised of the ex- 
tracellular domain of the IgE receptor and the mem- 
brane-spanning helix and cytoplasmic domain of the 
normal, or oncogenic, p185”c” tyrosine kinasc. These 
two fusion proteins are designated IgER/pl85”‘- and 
lgER/ ~185~“~, respectively. An advantage of the 
IgEl?/ ~185”” fusion proteins was that the levels of 
expression of these proteins in oocytes could be deter- 
mined by measuring the binding of labeled IgE to the 
fusion proteins [IS]. This differs from the case of p185”‘” 
for which the quantitation of protein expression 
through ligand binding assays has not been possible 
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Fig. ?. Schematic representation f restriction sites and primary struc- 
ture of the parent ~185”‘” and chimeric IpE reccptor/pl55”‘” con- 
structs. T.M. denotes the transmembrane domain. VIE(664) reprc- 
sents the normal and activating residues in the transmembrane s @ 
mentofp18S”“U. The orientation and complcmentarity of primers used 
in the hybrid-generating PCR reaction are also shown. Nontomple- 
mentary regions in each primer are denoted by dashed lines. 
since ~185~‘~ -specific ligands (e.g. growth factors) have 
not been definitively identified (although see ref. [17]). 
In addition, since protocols for crosslinking IgE recep- 
tor extracellular domains and for generating IgE recep 
tor oligomers have been established [18], the IgER/ 
p185”‘” chimeras provided a means for examining the 
possible involvement of protein-protein interactions 
(aggregation) in the activation of p185”‘” tyrosine ki- 
nase activity. 
Unlike the case for the EGF receptor, we did not find 
any conditions where either the normal neu tyrosine 
kinase (pl 85’“lhW ) alone, or the oncogenic form of 
neu(pl85 Y’u664) alone, was able to elicit GVBD in the 
oocytes. However, we did observe that after a period of 
24 days, some percentage of the oocytes (-3040%) 
that were injected with the mRNA for ~18Y’“~ (and to 
a much lesser extent when injected with the mRNA for 
pl 8SneU) began to show an abnormal morphology and 
ultimately died. The cell death elicited by the p185”‘” 
tyrosine kinases could be inhibited by >80% by deplet- 
ing the oocytes of extracellular Cn”’ (data not shown), 
similar to the case for the EGF receptor. 
Progesterone potently elicits GVBD, as has been doc- 
umented by a number of laboratories [cf. 191, and we 
find that the oncogenic form of the neu tyrosine kinase 
(pi&Y”‘-4) can accelerate this response (see Fig. 3 and 
Table I). Following the injection of the message for the 
p185s’“6” into oocytes, there was a significant shift in 
the half time for the progesterone-induced GVBD from 
a 1,* 4 1.5 8 8.5 B 7.6 6 5.6 6 0.5 10 IO.8 
Time (hours) 
Fig, 3. Expression of p18YJ”@ enhances the rate of progestcronc- 
induced oocyte mtlturation. Oocytes were injected with 50-75 ng of 
mRNA as described in Materials and Methods. 48 h following injec- 
tion sample- and water-injected control oocyte pools (approx. 50-60 
oocytes each) were exposed to Spg/rnl progesterone. The time to onset 
of GVBD is shown, 
-9-9.5 h (i.e. for control oocytes which were injected 
with water) to -5 h, The promotion of the progesterone- 
induced maturation was specifically elicited by 
p 1 85gluti1, with the injection of the message for ~185”~‘~ 
resulting in little or no enhancement (i.e. typically ~2%; 
set Fig. 3 and Table I, entries 1-3). In addition, when 
the lysine at position 758 of the ~185~“~~ protein was 
changed to an alanine residue, the resultant kinase-de- 
fective neu was unable to promote the progesterone- 
induced maturation event (see Table I, entries 4 and 5). 
Fig. 4 presents the results of experiments where the 
IgE receptor/p1 85”‘” chimeras were expressed in 
oocytes. Based on assays measuring the binding of ‘?‘I- 
IgE to IgER/p185”c” fusion proteins, we estimated that 
-5x1 O6 IgER/p185”‘” chimeras were expressed per 
oocyte in these experiments. As was observed with the 
~185@“~“, the IgER/pl85 du6[d chimera caused a signifi- 
Table I 
Etl’ects of microinjected mRNAs encoding the pl85”‘” tyrosinc kinase 
on progesterone’-stimulated oocyte maturation 
Injections 
- 













pl WuW mRNA 
p~8yd664”‘“758 (-kinase) mRNA 
p185 ~luasdalu75n (-kinase) mRNA 
IgERIpl S5Vu’bM mRNA 
IgER/p18SY’U”ti mRNA 
Y 13-259 (I 50 ndoocytc) 
IgER/plS5”‘1M mRNA + Y 13.259 (150 ndoocyte) 
ISER/p I85 duw mRNA -I- Y 13.259 (1% ng/oocyte) 
9.0 zt 0.2 
8.8 + 0.2 
5.6 5 0.5 
8.7 c 0.3 
8.8 z! 0.3 
8.6 2 0.3 
5.5 * 0.4 
8.4 f 0.2 
8.4 + 0.4 
5.4 c 0.5 
’ Progesterone was used at 5 ,@ml. 
?Standard deviations arc based on two experiments with each data 
point representing the average or approximately 30 oocytcs. 
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Fig. 4. Effect of chimeric proteins on progesterone-induced oocyte 
maturation. Injected oocytc pools (50-75 ng mRNA/oocyte, 50-60 
oocytetipool) were exposed to monomeric anti.DNP mouse IgE (10 
rg/ml) for 48 h post-injection. Subsequently, progesterone (5,up/ml) 
and cross-linking agent (DNP,-BSA, I ps/ml) were simultaneously 
added to the washed oocptes, The onset of GVBD was recorded as 
described. 
cant increase in the rate of progesterone-stimulated 
GVBD, whereas its non-mutated counterpart, IgER/ 
pl 8W”, caused only a minor reduction in the half life 
for GVBD relative to the rate measured following the 
injection of water. Here, again the substitution of an 
alanine residue at position 758 for a lysine residue elim- 
inates the ability of the IgER/p185g’U6M chimera to pro- 
mote the progesterone-stimulated GVBD event (data 
not shown). Taken together, these data indicate that the 
extracellular domain of pl85”‘” is not essential for the 
ability of the oncogenic form of ~185”‘” (i.e. ~185~‘“~~) 
to elicit a biological response, whereas a viable tyrosine 
kinase activity is essential for the stimulated GVBD by 
the neu proteins. 
It has been well documented that the binding of IgE 
to the extracellular domain of the IgE receptor, fol- 
lowed by the antigen-induced crosslinking of IgE- 
bound IgE receptor complexes, results in an activation 
of the receptor signaling pathways [18]. The results pre- 
sented in Fig. 4 show that the crosslinking of the IgER/ 
~185 v016G4 chimera, by the addition of I &ml dinitro- 
phenyl-conjugated BSA (DNP,,-BSA), resulted in an 
increase in the rate of the progesterone-stimulated 
GVBD, relative to the rate observed with IgERl 
P185’3’661 in the absence of crosslinking. The half time 
for progesterone-induced oocyte maturation was re- 
duced from -9 h to -7 h, which indicates that the 
crosslinked IgER/pl85 vn166) chimeras were about 50% as 
effective as the oncogenic form of ~185”‘” in eliciting 
?his specific biological response. The crosslinking of 
IgER/p185tilU664 chimeras was not observed to cause any 
significant change in the half-time for GVBD relative to 
that measured in the absence of crosslinking (data not 
shown). 
4. DISCUSSION 
The results described here suggest hat p185nc” does 
not fully mimic the EGF receptor in its ability to influ- 
ence cell cycle events in oocytes. In fact the EGF recap- 
tor appears to be one of the most effective agents known 
with regard to triggering oocyte maturation (where, for 
example, in our hands it clearly surpasses the ability of 
insulin to elicit a maturation event and at least equals 
the effectiveness of progesterone). However, we find 
that even the oncogenic form of pl85”‘” (pl85@‘-) 
shows little or no ability to stimulate spontaneous 
GVBD in oocytes. Thus these findings, together with 
the studies by DiFiore et al., in interleukin-3-dependent 
32D hematopoietic cells [ 141, lead to the conclusion that 
the EGF receptor and neu tyrosine kinases do not share 
identical cellular signaling pathways. 
The oncogenic form of p185”‘” does significantly en- 
hance the ability of progesterone to stimulate oxyte 
maturation. The molecular basis underlying the obser- 
vation that only the oncogenic form of p185”‘” is capa- 
ble of eliciting this enhancement is currently unknown. 
However, various groups have suggested that the single 
mutation within the membrane-spanning helix of 
p 185”‘” (at position 664) results in an increased tyrosine 
kinase activity [5-S], thus suggesting that a tyrosine 
phosphorylation event(s) is an important component of 
the enhancement of the progesterone-stimulated 
GVBD. The fact that this enhancement isnot observed 
with a kinase-defective form of ~185”“~ is consistent 
with such a notion. 
It is interesting that the pl 8YiuW and IgER/p1858’“6W 
proteins appear to have essentially identical abilities to 
promote the progesterone-stimulated maturation event. 
This indicates that the extracellular domain of ~185”‘” 
is not an essential component of the biological activities 
elicited by the oncogenic form of p185”‘“. However, the 
aggregation of the IgER extracellular domains of the 
IgEIUpl85”‘” chimera does appear to significantly in- 
crease the ability of a normal p18Sncu protein (i.c. con- 
taining valine at position 664) to enhance the progester- 
one-stimulated GVBD. This is consistent with an earlier 
suggestion [20] that the aggregation of p185”‘” causes an 
elevation of pl85”‘” tyrosine kinase activity. Nonethe- 
less, this aggregation event does not result in a facilita- 
tion of progesterone-induced GVBD comparable to 
that observed upon expression of ~185~‘“~. Possible 
explanations for this observation may involve an in- 
complete (or improper) aggregation of ~185”‘” follow- 
ing the antigen-induced crosslinking of the IgER ex- 
tracellular domains, or it may mean that the aggrega- 
tion of ~185 v”‘6M does not fully mimic the tertiary con- 
formation of ~185~“~. 
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Previous studies have suggested that the p21run GTP- 
binding proteins are downstream components of the 
signaling pathways of growth factor receptor/tyrosine 
kinases [21], and the microinjection of oncogenic forms 
of p2 1 r38 can elicit oocyte maturation 1221. Thus far, we 
have not found the injection of the neutralizing ~21’“’ 
antibody Y 13-2.59 ( 150 ng/oocyte) to have any effect on 
the ability of ~185 g’uW to promote the progesterone- 
induced maturation (see Table I, entries 8-10) or to 
influence the ability of the EGF receptor to elicit EGF- 
dependent oocyte maturation (data not shown), Future 
studies, aimed at comparing the effects of the ~21’“’ 
protein on oocyte maturation with those of the EGF 
receptor and p 185”‘“, should provide important infor- 
mation regarding the possible role of this GTP-binding 
protein in the signaling pathways of these tyrosine ki- 
nases. 
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